Cannoli: So from that graph it looks like orphan drugs have about a 45% FDA approval rate compared to 10% for non-orphan drugs. But since those are averages, some orphan drugs might have an even higher than 45% chance, based on advantages they might have over other orphans. Perhaps, MANF/Retinitis might have a better chance because of it's lack of toxicity problems? For Bascom Palmer to be so interested, Retinitis seems to have the deck stacked in it's favor.